Integrase Inhibitors: all 515 studies that test it

Page 4 of 6. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.

• Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir DisproxilStatus unknownNCT04903847Phase 4
• A Study of JNJ-56136379 in Healthy ParticipantsWithdrawnNCT04853524Phase 1
• Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)Active, not recruitingNCT04826562Phase 4
• Same-day Antiretroviral Therapy With BIC/F/TAFStatus unknownNCT04712058Not applicable
• Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'CompletedNCT04653194Phase 3
• Bictegravir/FTC/TAF for the Treatment of Primary HIV InfectionStatus unknownNCT04483674Phase 2
• A Test and Treat Strategy in New HIV Diagnosis.CompletedNCT04416906Phase 3
• Contribution of Dolutegravir to Obesity and Cardiovascular DiseaseCompletedNCT04340388Phase 4
• DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years OldActive, not recruitingNCT04337450Phase 2/3
• Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed AdultsStatus unknownNCT04311957Phase 4
• Biktarvy in Treatment-Naïve Late Presenters With HIV-1 InfectionCompletedNCT04296695Phase 4
• Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIVTerminatedNCT04249037Phase 4
• Second-line Switch to Dolutegravir StudyCompletedNCT04229290Phase 4
• Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).Status unknownNCT04225325Phase 4
• Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of PolymedicationStatus unknownNCT04222283Phase 4
• Inflammation and Co-Infections in D²EFTWithdrawnNCT04183738Phase 4
• Drug Interactions Between Dolutegravir and Escalating Doses of RifampicinCompletedNCT04166474Phase 4
• Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based RegimenStatus unknownNCT04155554Phase 3
• Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically SuppressedStatus unknownNCT04132674Phase 4
• Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF)CompletedNCT04054089Phase 4
• ANRS 12372 MODERATO StudyCompletedNCT04022967Phase 3
• Nucleosides And Darunavir/Dolutegravir In AfricaStatus unknownNCT03988452Phase 3
• How Does Antiretroviral Therapy Affect Coronary Atherosclerosis: a Serial CT StudyWithdrawnNCT03986697Phase 4
• Combination Antiretroviral Therapy (cART) for PBCCompletedNCT03954327Phase 2
• BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) StudyStatus unknownNCT03916328Phase 4
• Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FASTStatus unknownNCT03858478Phase 4
• Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.WithdrawnNCT03813979Phase 4
• Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD StudyStatus unknownNCT03732625Phase 4
• Efficacy, Safety and Pharmacokinetics of DTG With RIFCompletedNCT03731559Phase 2
• Empiric Treatment for Acute HIV in the EDStatus unknownNCT03711253Phase 4
• Body Composition Sub-study of the D2EFT TrialCompletedNCT03675815Phase 4
• Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)WithdrawnNCT03549689Phase 2
• Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution TherapyStatus unknownNCT03549312Phase 4
• Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.Status unknownNCT03539224Phase 2
• Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1CompletedNCT03502005Phase 4
• Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)CompletedNCT03499483Phase 4
• Dual Obstructive Sleep Apnea TherapyStatus unknownNCT03435731Not applicable
• Same-Day Treatment With Genvoya vs. EFV/TDF/3TCWithdrawnNCT03405194Not applicable
• Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current RegimenTerminatedNCT03333083Phase 3
• Phase 4 Study of Dolutegravir (DTG) in Russian FederationCompletedNCT03314064Phase 4
• Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TCStatus unknownNCT03275701Not applicable
• Dolutegravir in Pregnant HIV Mothers and Their NeonatesCompletedNCT03249181Phase 3
• Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected SubjectsCompletedNCT03224338Phase 2
• A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy VolunteersStatus unknownNCT03199690Phase 1
• ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral TherapyCompletedNCT03122262Phase 3
• The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy VolunteersCompletedNCT03094507Phase 1
• Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral MedicationCompletedNCT03092206Phase 1
• Dolutegravir and Darunavir Evaluation in Adults Failing TherapyStatus unknownNCT03017872Phase 4
• National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) InfectionCompletedNCT02987530Phase 3
• Kinetics of HIV-RNA Decay in Seminal Plasma of Men Treated by Dolutegravir at the Time of Primary HIV InfectionCompletedNCT02976259Phase 3
• Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing CureCompletedNCT02961829Not applicable
• Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible TabletCompletedNCT02893488Phase 1
• Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1Active, not recruitingNCT02881320Phase 2/3
• Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).CompletedNCT02868580Phase 2
• A Study to Evaluate the Effect of High Fat Meal on CabotegravirCompletedNCT02799264Phase 1
• Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited SettingsCompletedNCT02777229Phase 3
• Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)CompletedNCT02741557Phase 1
• Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose CombinationsCompletedNCT02738931Phase 1
• A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176CompletedNCT02715479Phase 1
• Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV InfectionCompletedNCT02691065Phase 4
• Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject DrugsTerminatedNCT02659761Phase 4
• Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV InfectionActive, not recruitingNCT02656511Phase 4
• Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected PatientsTerminatedNCT02596334Phase 3
• A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed PatientsCompletedNCT02572947Phase 2
• Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole TabletCompletedNCT02569346Phase 1
• Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance RegimenTerminatedNCT02566707Phase 2
• Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 InfectionStatus unknownNCT02551523Phase 2
• A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)CompletedNCT02527096Phase 2
• HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based RegimenCompletedNCT02513147Phase 4
• SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and OverCompletedNCT02509195Phase 4
• Dolutegravir Impact on Residual ReplicationCompletedNCT02500446Phase 4
• Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated ToxicityWithdrawnNCT02499978Phase 2/3
• Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500CompletedNCT02489487Phase 1
• Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal DiseaseCompletedNCT02487706Phase 4
• Dual Therapy With Boosted Darunavir + DolutegravirCompletedNCT02486133Phase 3
• Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose CombinationCompletedNCT02475135Phase 1
• Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveWithdrawnNCT02470650Phase 4
• Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South AfricaWithdrawnNCT02462772Phase 2
• The Dolutegravir Antiretroviral Mono-Therapy for HIV TrialCompletedNCT02401828Phase 4
• A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy VolunteersCompletedNCT02354950Phase 1
• Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal ImpairmentCompletedNCT02354937Phase 1
• Relative Bioavailability Study of Phase III Tablet Formulation of CabotegravirCompletedNCT02345707Phase 1
• Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted DarunavirStatus unknownNCT02337322Phase 4
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple TherapyCompletedNCT02302547Phase 3
• Efavirenz to Dolutegravir Switch in Patients With CNS ToxicityStatus unknownNCT02285374Phase 4
• Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)TerminatedNCT02247687Phase 3
• Dolutegravir Interactions With Artemisinin-based Combination TherapiesCompletedNCT02242799Phase 1
• SSAT061: PK of DTG and EVT/COBI in Healthy VolunteersCompletedNCT02219217Phase 1
• The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure ProphylaxisCompletedNCT02211690Phase 4
• Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot StudyCompletedNCT02211482Phase 4
• Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected PatientsCompletedNCT02210715Phase 4
• Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.CompletedNCT02198443Phase 4
• Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy VolunteersCompletedNCT02182375Phase 1
• Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female SubjectsCompletedNCT02159131Phase 1
• Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)CompletedNCT02098837Phase 4
• Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult SubjectsCompletedNCT02082808Phase 1
• Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD)CompletedNCT02067767Phase 2
• Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult SubjectsCompletedNCT02064374Phase 1
• A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult SubjectsCompletedNCT02059031Phase 1
• Study to Evaluate the Effect of GSK1265744 on Cardiac ConductionCompletedNCT02027454Phase 1

← Integrase Inhibitors overview